An interventional study of Phototherapy in Uncomplicated Neonatal Hyperbilirubinemia, sponsored by University of Aarhus. Completed at 1 site in Denmark. Open to participants aged 33 Weeks and older. Per ClinicalTrials.gov, last updated 2014-06-03.
Sponsored by University of Aarhus · Not applicable, Interventional, and Treatment
The optimal wavelength for phototherapy for neonatal jaundice remains to be clarified by clinical studies. Previous iv vivo studies have shown that turquoise light at wavelength about 490 nm is more efficacious than blue light at wavelength 460 nm, which is the golden standard in phototherapy treatment today. Though, previous studies used light tubes, today we use light emitting diodes (LED'S).
The overall aim of this study was therefore to compare the efficacy of turquoise LED's versus blue LED's for decreasing total serum bilirubin in neonates with gestational age > 33 weeks and uncomplicated hyperbilirubinemia.
105 studies on the registry are indexed under Jaundice, Neonatal; 27 are open to participants now.
This study's enrollment of 90 is below the median of 134 across 74 interventional studies indexed under Jaundice, Neonatal.
Browse Jaundice, Neonatal studies →University of Aarhus is the lead sponsor of 1,274 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other: Phototherapy
Other: Phototherapy
The infants were randomized to phototherapy with either blue og turquoise light
Decrease in total serum bilirubin
The infants were treated with phototherapy for 24 hours, which is the standard treatment.
Time frame: 24 hours
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Aarhus